使美国食品药品监督管理局的加速批准途径现代化。 - Suppr

Suppr

超能文献

Modernising the US FDA's Accelerated Approval pathway.

作者信息

Benjamin David J, Lythgoe Mark P

机构信息

Hoag Family Cancer Institute, Newport Beach, CA 92663, USA.

Department of Surgery and Cancer, Imperial College, London, UK; Hammersmith Hospital, London, UK.

出版信息

Lancet Oncol. 2023 Mar;24(3):203-205. doi: 10.1016/S1470-2045(23)00020-7.

DOI:10.1016/S1470-2045(23)00020-7

PMID:36858720

Abstract

摘要

相似文献

Modernising the US FDA's Accelerated Approval pathway.使美国食品药品监督管理局的加速批准途径现代化。

Lancet Oncol. 2023 Mar;24(3):203-205. doi: 10.1016/S1470-2045(23)00020-7.

Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval.加速批准的癌症药物的临床获益评估。

JAMA Intern Med. 2019 Jul 1;179(7):906-913. doi: 10.1001/jamainternmed.2019.0462.

Extending the US Food and Drug Administration's Postmarket Authorities.扩大美国食品和药物管理局的上市后监管权。

JAMA Health Forum. 2023 Jun 2;4(6):e231313. doi: 10.1001/jamahealthforum.2023.1313.

Analysis of FDA's Accelerated Approval Program Performance December 1992-December 2021.分析 FDA 的加速审批计划表现 1992 年 12 月至 2021 年 12 月。

Ther Innov Regul Sci. 2022 Sep;56(5):698-703. doi: 10.1007/s43441-022-00430-z. Epub 2022 Jul 28.

Reforming Reimbursement for the US Food and Drug Administration's Accelerated Approval Program to Support State Medicaid Programs.改革美国食品和药物管理局的加速审批计划的报销制度，以支持州医疗补助计划。

JAMA Health Forum. 2022 Nov 4;3(11):e224115. doi: 10.1001/jamahealthforum.2022.4115.

Recent Trends in Medicaid Spending and Use of Drugs With US Food and Drug Administration Accelerated Approval.近期美国医疗补助计划（Medicaid）支出与使用经美国食品药品监督管理局加速批准药物的趋势。

JAMA Health Forum. 2021 Oct 8;2(10):e213177. doi: 10.1001/jamahealthforum.2021.3177. eCollection 2021 Oct.

Evaluating the evidence behind the surrogate measures included in the FDA's table of surrogate endpoints as supporting approval of cancer drugs.评估美国食品药品监督管理局（FDA）替代终点表格中所包含的替代指标背后的证据，以支持癌症药物的批准。

EClinicalMedicine. 2020 Apr 13;21:100332. doi: 10.1016/j.eclinm.2020.100332. eCollection 2020 Apr.

FDA's Flexibility in Subpart H Approvals: Assessing Quantum of Effectiveness Evidence.美国食品药品监督管理局在H子部分审批中的灵活性：评估有效性证据的数量

Food Drug Law J. 2016 Aug;71(1):135-157.

Potential policy reforms to strengthen the accelerated approval pathway.加强加速批准途径的潜在政策改革。

J Comp Eff Res. 2021 Nov;10(16):1177-1186. doi: 10.2217/cer-2021-0184. Epub 2021 Aug 24.

Global consequences of the US FDA's accelerated approval of cancer drugs.美国食品药品监督管理局加速批准癌症药物的全球影响。

Lancet Oncol. 2022 Feb;23(2):201-203. doi: 10.1016/S1470-2045(21)00709-9.

引用本文的文献

Current landscape of innovative drug development and regulatory support in China.中国创新药物研发与监管支持的现状

Signal Transduct Target Ther. 2025 Jul 22;10(1):220. doi: 10.1038/s41392-025-02267-y.

Strength of clinical evidence supporting the United States Food and Drug Administration Accelerated Approvals from 2015 to 2022.支持美国食品药品监督管理局2015年至2022年加速批准的临床证据强度。

BMC Med. 2024 Dec 18;22(1):587. doi: 10.1186/s12916-024-03800-6.

Expediting treatments in the 21st century: orphan drugs and accelerated approvals.加速 21 世纪的治疗进程：孤儿药与加速审批

Orphanet J Rare Dis. 2024 Nov 8;19(1):418. doi: 10.1186/s13023-024-03398-1.

Evidence of pre-approval clinical trial supporting the granted conditional approval for novel cancer drugs in China between 2015 and 2022.2015年至2022年期间支持中国新型癌症药物获得有条件批准的批准前临床试验证据。

EClinicalMedicine. 2023 Aug 24;63:102177. doi: 10.1016/j.eclinm.2023.102177. eCollection 2023 Sep.

Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.2006-2021 年接受美国加速批准和欧盟有条件上市许可途径双重批准的新型肿瘤药物比较：一项横断面研究。

BMJ Open. 2023 Jun 7;13(6):e069132. doi: 10.1136/bmjopen-2022-069132.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验